DeepMed Research

POLYSAN Scientific & Technological Pharmaceutical Company

Country

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

A Multicenter, Randomized, Double-blind Study of REAMBERIN® 1.5% in Rehydration Therapy of Diabetic Ketoacidosis

Phase 2

Recruiting

Conditions: Diabetic Ketoacidosis

Interventions: Drug: Reamberin
Drug: Placebo

First Posted Date: 2025-05-02

Last Posted Date: 2025-05-16

Lead Sponsor: POLYSAN Scientific & Technological Pharmaceutical Company

Target Recruit Count: 312

Registration Number: NCT06955416

Locations: 🇷🇺
Kuzbass Clinical Hospital of Emergency Medical Care named after M.A. Podgorbunsky, Kemerovo, Russian Federation
🇷🇺
State Budgetary Institution of Healthcare of the Arkhangelsk Region "First City Clinical Hospital named after E.E. Volosevich", Arkhangelsk, Russian Federation
🇷🇺
Regional budgetary healthcare institution "Ivanovo regional clinical hospital", Ivanovo, Russian Federation

Evaluation of the Efficacy of Permanent Course Combined Therapy With CYTOFLAVIN® Intravenous Solution and CYTOFLAVIN Tablets, at 2-3 Stages of Rehabilitation of Patients With Post Intensive Care Syndrome

Recruiting

Conditions: Ischemic Stroke

First Posted Date: 2024-12-16

Last Posted Date: 2025-04-06

Lead Sponsor: POLYSAN Scientific & Technological Pharmaceutical Company

Target Recruit Count: 90

Registration Number: NCT06735898

Locations: 🇷🇺
Brain Institute Clinic, Ekaterinburg, Sverdlovsk region, Russian Federation

Observational Study of Efficiency of Cytoflavin, in Patients With Ischemic Stroke Not Receiving Reperfusion Therapy

Recruiting

Conditions: Stroke, Acute
Stroke, Ischemic

Interventions: Drug: Cytoflavin

First Posted Date: 2024-07-23

Last Posted Date: 2025-04-18

Lead Sponsor: POLYSAN Scientific & Technological Pharmaceutical Company

Target Recruit Count: 562

Registration Number: NCT06514976

Locations: 🇷🇺
City Mariinsky Hospital, Saint Petersburg, Russian Federation
🇷🇺
Alexandrovskaya hospital, Saint Petersburg, Russian Federation
🇷🇺
"Ivanovo Regional Clinical Hospital", Ivanovo, Russian Federation

and more 14 locations

Study of Safety and Efficacy of the Drug Cycloferone in Patients with Acute Respiratory Viral Infection

Completed

Conditions: Acute Respiratory Viral Infection

Interventions: Drug: Cycloferone

First Posted Date: 2024-02-29

Last Posted Date: 2024-12-16

Lead Sponsor: POLYSAN Scientific & Technological Pharmaceutical Company

Target Recruit Count: 742

Registration Number: NCT06286254

Locations: 🇷🇺
Сity clinic No. 44, Saint Petersburg, Russian Federation
🇷🇺
Medical Center Energiya Zdoroviy, Saint Petersburg, Russian Federation
🇷🇺
Medical Center Oris, Saint Petersburg, Russian Federation

and more 10 locations

Comparative Study of REMAXA®, Enteric-coated Tablets and REMAXOL®, Solution for Infusions, in Intrahepatic Cholestasis

Phase 2

Completed

Conditions: Cholestasis, Intrahepatic

Interventions: Drug: Remaxa, enteric-coated tablets
Drug: Remaxol
Drug: Placebo

First Posted Date: 2023-12-27

Last Posted Date: 2025-04-29

Lead Sponsor: POLYSAN Scientific & Technological Pharmaceutical Company

Target Recruit Count: 328

Registration Number: NCT06183242

Locations: 🇷🇺
Research Center for Eco-safety, Ltd., Saint Petersburg, Russian Federation
🇷🇺
City Hospital of the Holy Martyr Elizabeth, Saint-Petersburg, Russian Federation
🇷🇺
Medical Company "Hepatologist" Ltd., Samara, Russian Federation

Cycloferon for Post-exposure Prophylaxis of Acute Respiratory Viral Infections and Influenza

Phase 3

Completed

Conditions: Influenza
Acute Respiratory Infection

Interventions: Drug: Cycloferon
Drug: Placebo

First Posted Date: 2023-12-27

Last Posted Date: 2025-04-29

Lead Sponsor: POLYSAN Scientific & Technological Pharmaceutical Company

Target Recruit Count: 166

Registration Number: NCT06183229

Locations: 🇷🇺
Research Center for Eco-safety, Ltd., Saint Petersburg, Russian Federation
🇷🇺
City Outpatient Clinic #117, Saint-Petersburg, Russian Federation

Cytoflavin in the Complex Rehabilitation of Stroke Patients

Phase 3

Recruiting

Conditions: Stroke

Interventions: Drug: Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid)
Drug: Placebo

First Posted Date: 2023-07-07

Last Posted Date: 2024-12-13

Lead Sponsor: POLYSAN Scientific & Technological Pharmaceutical Company

Target Recruit Count: 196

Registration Number: NCT05935787

Locations: 🇷🇺
City General Hospital №2, Saint Petersburg, Russian Federation
🇷🇺
Saint-Petersburg I.I.Dzanelidze Research Institute of Emergency Medicine, Saint Petersburg, Russian Federation
🇷🇺
City Hospital №40 of the Kurortny District, Saint Petersburg, Russian Federation

Remaxol® Used in the Treatment of Patients With Gallstone Disease Complicated With Obstructive Jaundice

Recruiting

Conditions: Gallstone Disease
Obstructive Jaundice

Interventions: Drug: Remaxol

First Posted Date: 2023-07-03

Last Posted Date: 2025-04-20

Lead Sponsor: POLYSAN Scientific & Technological Pharmaceutical Company

Target Recruit Count: 286

Registration Number: NCT05928286

Locations: 🇷🇺
Krai Clinical Hospital, Barnaul, Russian Federation
🇷🇺
Hospital for War Veterans, Kazan, Russian Federation
🇷🇺
Pavlov Ryazan State Medical University, Ryazan, Russian Federation

and more 6 locations

Remaxol® in Patients with Drug-induced Liver Injuries During Cancer Chemotherapy

Recruiting

Conditions: Cancer
Drug Induced Liver Injury

Interventions: Drug: Remaxol

First Posted Date: 2023-03-29

Last Posted Date: 2024-12-16

Lead Sponsor: POLYSAN Scientific & Technological Pharmaceutical Company

Target Recruit Count: 368

Registration Number: NCT05789797

Locations: 🇷🇺
North-West Center of Evidence-Based Medicine, Saint Petersburg, Russian Federation
🇷🇺
Republican Clinical Cancer Centre, Ufa, Russian Federation
🇷🇺
St. Petersburg State Budget-Funded Health Institution City Clinical Cancer Centre, St. Petersburg, Russian Federation

and more 2 locations

Study of Safety and Efficiency of the Drug Reamberin® in the Intensive Care of Patients With Acute Ethanol Intoxication

Completed

Conditions: Ethanol Intoxication

Interventions: Drug: Reamberin

First Posted Date: 2023-02-08

Last Posted Date: 2025-04-18

Lead Sponsor: POLYSAN Scientific & Technological Pharmaceutical Company

Target Recruit Count: 296

Registration Number: NCT05715723

Locations: 🇷🇺
KORSAKOV Medical Center, Moscow, Russian Federation
🇷🇺
Negovsky Research Institute of General Intensive Care Medicine, Moscow, Russian Federation
🇷🇺
City Clinical Hospital of Emergency Medical Care, Kaliningrad, Russian Federation

and more 15 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy